You are here

Home » Content

Methicillin-Resistant Staphylococcus aureus: A Mini Review

Journal Name:

  • International Journal of Medical Research & Health Sciences

Publication Year:

  • 2018

Key Words:

Author Name
Abstract (2. Language): 
Methicillin-resistant Staphylococcus aureus (MRSA) which emerged in hospitals in 1961 is now a leading cause of associated healthcare infections. The MRSA which is a Staphylococcus infection remarkably developed resistance to methicillin which was used to treat it. This review covers the epidemiology, pathophysiology, clinical manifestations, diagnostic measures, and effective management of MRSA. Currently, MRSA infection is encountered in small community hospitals, which leads to community-acquired MRSA (CA-MRSA) when the patients are discharged and introduce the strain into the community. MRSA can lead to diverse infection such as skin and soft tissue infections, bone and joint infections, and acute bacterial endocarditis. MRSA incidence is increasing in the population, and therapeutic measures are few and accompanied by diverse side effects notably the ability to develop resistance by S. aureus. Therefore, a well-formulated strategy which will prevent the spread of the pathogen is always a priority for healthcare providers. It is noteworthy to state that Vancomycin is still the first line drug although a Vancomycinresistant strain has been reported.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-methicillin-resistant-staphylococcus-aureus-mini-review.pdf
  • 1
122
127
  • English

REFERENCES

References: 

[1] Kuroda, Makoto, et al. “Whole genome sequencing of methicillin-resistant Staphylococcus aureus.” The Lancet,
Vol. 357, No. 9264, 2001, pp. 1225-40.
[2] Tsunokai, Glenn T., Allison R. McGrath, and Lurdes Hernandez-Hernandez. “Early sexual initiation and HIV
awareness among Asian American adolescents.” Journal of Asian American Studies, Vol. 15, No. 3, 2012, pp.
299-325.
[3] Corriere, Mark D., and Catherine F. Decker. “MRSA: An evolving pathogen.” Disease-a-Month, Vol. 54, No.
12, 2008, pp. 751-55.
[4] Chambers, Henry F., and Frank R. De Leo. “Waves of resistance: Staphylococcus aureus in the antibiotic
era.” Nature Reviews Microbiology, Vol. 7, No. 9, 2009, pp. 629-41.
[5] Enright, Mark C., et al. “The evolutionary history of methicillin-resistant Staphylococcus aureus
(MRSA).” Proceedings of the National Academy of Sciences, Vol. 99, No. 11, 2002, pp. 7687-92.
[6] David, Michael Z., and Robert S. Daum. “Community-associated methicillin-resistant Staphylococcus aureus:
epidemiology and clinical consequences of an emerging epidemic.” Clinical Microbiology Reviews, Vol. 23, No.
3, 2010, pp. 616-87.
[7] Tong, Steven YC, et al. “Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical
manifestations, and management.” Clinical Microbiology Reviews, Vol. 28, No. 3, 2015, pp. 603-61.
[8] Ito, Teruyo, et al. “Novel type V Staphylococcal cassette chromosome mec driven by a novel cassette chromosome
recombinase, ccrC.” Antimicrobial Agents and Chemotherapy, Vol. 48, No. 7, 2004, pp. 2637-51.
Chukwunonso, et al. Int J Med Res Health Sci 2018, 7(1): 122-127
127
[9] Mediavilla, José R., et al. “Global epidemiology of community-associated methicillin resistant Staphylococcus
aureus (CA-MRSA).” Current Opinion in Microbiology, Vol. 15, No. 5, 2012, pp. 588-95.
[10] Centers for Disease Control and Prevention. “Staphylococcus aureus with reduced susceptibility to vancomycin-
United States, 1997.” Morbidity and Mortality Weekly Report, No. 46, 1997, 765-66.
[11] Harkins, Catriona P., et al. “Methicillin resistant Staphylococcus aureus emerged long before the introduction of
methicillin in to clinical practice.” bioRxiv, 2017, p. 122408.
[12] Gomes, A.R., Henrik Westh, and H. De Lencastre. “Origins and evolution of methicillin-resistant Staphylococcus
aureus clonal lineages.” Antimicrobial Agents and Chemotherapy, Vol. 50, No. 10, 2006, pp. 3237-44.
[13] Stefani, Stefania, et al. “Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and
harmonisation of typing methods.” International Journal of Antimicrobial Agents, Vol. 39, No. 4, 2012, pp.
273-82.
[14] Temesgen, Zelalem, Larry M. Baddour, and James M. Steckelberg, editors. Mayo Clinic Infectious Diseases
Board Review. Oxford University Press, USA, 2011.
[15] Bassetti, Matteo, Elena Nicco, and Malgorzata Mikulska. “Why is community-associated MRSA spreading
across the world and how will it change clinical practice?” International Journal of Antimicrobial Agents, Vol.
34, 2009, pp. S15-S19.
[16] Harris, Allyssa L., and Heidi Collins Fantasia. “Community-associated MRSA infections in women.” The
Journal for Nurse Practitioners, Vol. 6, No. 6, 2010, pp. 435-41.
[17] Cunha, B. A. “Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial
therapy.” Clinical Microbiology and Infection, Vol. 11, No. s4, 2005, pp. 33-42.
[18] Brown, Derek FJ, et al. “Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant
Staphylococcus aureus (MRSA).” Journal of Antimicrobial Chemotherapy, Vol. 56, No. 6, 2005, pp. 1000-18.
[19] Fernando, A.M.R., Susan McQueen, and Mike Sharland. “Coping with MRSA.” Current Paediatrics, Vol. 15,
No. 5, 2005, pp. 437-42.
[20] Page, Malcolm GP. “Anti-MRSA β-lactams in development.” Current Opinion in Pharmacology, Vol. 6, No. 5,
2006, pp. 480-85.
[21] Ferry, Tristan, and Jerome Etienne. “Community acquired MRSA in Europe.” BMJ: British Medical Journal, Vol.
335, No. 7627, 2007, p. 947.
[22] Aaron, Harold. “The Medical Letter on Drugs and Therapeutics.” Canadian Medical Association Journal, Vol.
84, No. 19, 1961, p. 1082.
[23] May, Todd J., and Sarah Safranek. “When should you suspect community-acquired MRSA? How should you
treat it?” Clinical Inquiries, 2009 (MU), 2009.
[24] Van Bambeke, Françoise, et al. “The bacterial envelope as a target for novel anti-MRSA antibiotics.” Trends in
Pharmacological Sciences, Vol. 29, No. 3, 2008, pp. 124-34.
[25] Daum, Robert S. “Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.” New
England Journal of Medicine, Vol. 357, No. 4, 2007, pp. 380-90.
[26] Peeters, Michael J., and Juan C. Sarria. “Clinical characteristics of linezolid-resistant Staphylococcus aureus
infections.” The American Journal of the Medical Sciences, Vol. 330, No. 2, 2005, pp. 102-04.
[27] Swartz, Morton N. “Cellulitis.” New England Journal of Medicine, Vol. 350, No. 9, 2004, pp. 904-12.
[28] Chang, Soju, et al. “Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance
gene.” New England Journal of Medicine, Vol. 348, No. 14, 2003, pp. 1342-47.
[29] Wernitz, M.H., et al. “Effectiveness of a hospital-wide selective screening programme for methicillinresistant
Staphylococcus aureus (MRSA) carriers at hospital admission to prevent hospital-acquired MRSA
infections.” Clinical Microbiology and Infection, Vol. 11, No. 6, 2005, pp. 457-65.

Thank you for copying data from http://www.arastirmax.com